20240710-西南证券-和黄医药-00013.HK-商业化表现靓眼_管线持续释放创新潜力_5页_1mb

Andver Pharmaceuticals (013-HK) Research Report Summary

Key Points

On July 9th, Andver Pharmaceuticals held a research and development conference where the management team presented updates from several ongoing clinical trials. Highlights included:

• ESLIM-01 (Soticlelimab): Positive Phase 3 results for the treatment of Immune Thrombocytopenic Purpura (ITP), showing a high sustained response rate of 484% compared to 0% in the placebo group.
• ESLIM-02 (Soticlelimab): Ongoing Phase 2/3 studies for Warm-Antibody Type Autoimmune Hemolytic Anemia.
• Savolitinib: Phase 2/3 studies for pancreatic ductal adenocarcinoma.
• HMPL-306: A Phase 3 study for Acute Myeloid Leukemia.

Fruquintinib Commercialization

Fruquintinib, approved in the US in November 2023, has generated significant revenue. As of March 2024, its sales in the US exceeded USD 65 million. Further expansion is expected with regulatory approval in the EU and Japan, and ongoing clinical applications.

Savolitinib Advancement

Savolitinib became available in China for treating first and second-line Non-Small Cell Lung Cancer mutations in March 2024. The Phase 3 study (SACHI) is nearly complete, with a possible FDA meeting scheduled for the end of the year regarding new drug application.

Financials & Performance

• Revenue Projections: The company's revenue for 2024-2026 is expected to reach USD 66 billion, USD 88 billion, and USD 96 billion, respectively with a significant growth trajectory.
• Profitability: The company continues to demonstrate high growth in its net profits and earnings per share.
• Valuation: The P/E ratio ranges from 29.45 to 85.3, reflecting strong investor confidence.

Risk Management

The company highlights several potential risks including but not limited to:

• Unconfirmed clinical trial results.
• Potential delays in medication commercialization processes.
• Increased competition and possible pricing pressure on drugs.

Conclusion

Andver Pharmaceuticals maintains an "Buy" recommendation based on expected performance with continued innovation and advancements in key drug pipelines.